Unlock tomorrow – be part of a passionate group working to make a difference
Celcuity is a clinical-stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them. Our lead product candidate, gedatolisib, is a potential first-in-class dual pan-PI3K/mTOR inhibitor. Multiple Phase 1b/2 and Phase 3 clinical trials in breast, prostate, and other solid tumor indications are ongoing.

